394 related articles for article (PubMed ID: 19281091)
1. Higher lung deposition with Respimat Soft Mist inhaler than HFA-MDI in COPD patients with poor technique.
Brand P; Hederer B; Austen G; Dewberry H; Meyer T
Int J Chron Obstruct Pulmon Dis; 2008; 3(4):763-70. PubMed ID: 19281091
[TBL] [Abstract][Full Text] [Related]
2. A review of ipratropium bromide/fenoterol hydrobromide (Berodual) delivered via Respimat Soft Mist Inhaler in patients with asthma and chronic obstructive pulmonary disease.
Kässner F; Hodder R; Bateman ED
Drugs; 2004; 64(15):1671-82. PubMed ID: 15257628
[TBL] [Abstract][Full Text] [Related]
3. Improved delivery of ipratropium bromide/fenoterol from Respimat Soft Mist Inhaler in patients with COPD.
Kilfeather SA; Ponitz HH; Beck E; Schmidt P; Lee A; Bowen I; Hesse Ch
Respir Med; 2004 May; 98(5):387-97. PubMed ID: 15139567
[TBL] [Abstract][Full Text] [Related]
4. Respimat Soft Mist inhaler versus hydrofluoroalkane metered dose inhaler: patient preference and satisfaction.
Schürmann W; Schmidtmann S; Moroni P; Massey D; Qidan M
Treat Respir Med; 2005; 4(1):53-61. PubMed ID: 15725050
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the aerosol velocity and spray duration of Respimat Soft Mist inhaler and pressurized metered dose inhalers.
Hochrainer D; Hölz H; Kreher C; Scaffidi L; Spallek M; Wachtel H
J Aerosol Med; 2005; 18(3):273-82. PubMed ID: 16181002
[TBL] [Abstract][Full Text] [Related]
6. Reduced Environmental Impact of the Reusable Respimat
Hänsel M; Bambach T; Wachtel H
Adv Ther; 2019 Sep; 36(9):2487-2492. PubMed ID: 31317391
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of ipratropium bromide plus fenoterol inhaled via Respimat Soft Mist Inhaler vs. a conventional metered dose inhaler plus spacer in children with asthma.
von Berg A; Jeena PM; Soemantri PA; Vertruyen A; Schmidt P; Gerken F; Razzouk H
Pediatr Pulmonol; 2004 Mar; 37(3):264-72. PubMed ID: 14966821
[TBL] [Abstract][Full Text] [Related]
8. Respimat (a new soft mist inhaler) delivering fenoterol plus ipratropium bromide provides equivalent bronchodilation at half the cumulative dose compared with a conventional metered dose inhaler in asthmatic patients.
Kunkel G; Magnussen H; Bergmann K; Juergens UR; de Mey C; Freund E; Hinzmann R; Beckers B
Respiration; 2000; 67(3):306-14. PubMed ID: 10867600
[TBL] [Abstract][Full Text] [Related]
9. Improved delivery of fenoterol plus ipratropium bromide using Respimat compared with a conventional metered dose inhaler.
Goldberg J; Freund E; Beckers B; Hinzmann R
Eur Respir J; 2001 Feb; 17(2):225-32. PubMed ID: 11334124
[TBL] [Abstract][Full Text] [Related]
10. Deposition of corticosteroid aerosol in the human lung by Respimat Soft Mist inhaler compared to deposition by metered dose inhaler or by Turbuhaler dry powder inhaler.
Pitcairn G; Reader S; Pavia D; Newman S
J Aerosol Med; 2005; 18(3):264-72. PubMed ID: 16181001
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of ipratropium bromide/salbutamol sulphate administered in a hydrofluoroalkane metered-dose inhaler for the treatment of COPD.
Bhattacharya A; Bhargava S; Singh V; Talwar D; Whig J; Rebello J; Purandare S; Gogtay J
Int J Chron Obstruct Pulmon Dis; 2016; 11():1469-76. PubMed ID: 27418820
[TBL] [Abstract][Full Text] [Related]
12. Preliminary data from phase II studies with Respimat, a propellant-free soft mist inhaler.
Pavia D; Moonen D
J Aerosol Med; 1999; 12 Suppl 1():S33-9. PubMed ID: 10623340
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO.
Huchon G; Hofbauer P; Cannizzaro G; Iacono P; Wald F
Eur Respir J; 2000 Apr; 15(4):663-9. PubMed ID: 10780756
[TBL] [Abstract][Full Text] [Related]
14. [Chinese expert consensus on standardized inhaler device application in stable chronic airway diseases (2023)].
Inhalation Therapy and Respiratory Rehabilitation Group, Respiratory Equipment Committee of China Association of Medical Equipment
Zhonghua Jie He He Hu Xi Za Zhi; 2023 Nov; 46(11):1055-1067. PubMed ID: 37914418
[TBL] [Abstract][Full Text] [Related]
15. Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler.
Hodder R; Pavia D; Dewberry H; Alexander K; Iacono P; Ponitz H; Beck E
Respir Med; 2005 Sep; 99(9):1087-95. PubMed ID: 15893465
[TBL] [Abstract][Full Text] [Related]
16. Fenoterol delivery by Respimat soft mist inhaler versus CFC metered dose inhaler: cumulative dose-response study in asthma patients.
Vincken W; Dewberry H; Moonen D
J Asthma; 2003 Sep; 40(6):721-30. PubMed ID: 14580004
[TBL] [Abstract][Full Text] [Related]
17. Improved delivery of ipratropium bromide using Respimat (a new soft mist inhaler) compared with a conventional metered dose inhaler: cumulative dose response study in patients with COPD.
Iacono P; Velicitat P; Guemas E; Leclerc V; Thébault JJ
Respir Med; 2000 May; 94(5):490-5. PubMed ID: 10868713
[TBL] [Abstract][Full Text] [Related]
18. Development of a novel digital breath-activated inhaler: Initial particle size characterization and clinical testing.
Kesten S; Israel E; Li G; Mitchell J; Wise R; Stern T
Pulm Pharmacol Ther; 2018 Dec; 53():27-32. PubMed ID: 30201410
[TBL] [Abstract][Full Text] [Related]
19. Delivery of fenoterol via Respimat, a novel 'soft mist' inhaler. a randomised, double-blind (within device), placebo-controlled, cross-over, dose-ranging study in asthmatic patients.
van Noord JA; Smeets JJ; Creemers JP; Greefhorst LP; Dewberry H; Cornelissen PJ
Respiration; 2000; 67(6):672-8. PubMed ID: 11124651
[TBL] [Abstract][Full Text] [Related]
20. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
